Longeveron Future Growth
Future criteria checks 2/6
Longeveron is forecast to grow earnings and revenue by 47.7% and 65.2% per annum respectively while EPS is expected to grow by 76% per annum.
Key information
47.7%
Earnings growth rate
76.0%
EPS growth rate
| Biotechs earnings growth | 27.3% |
| Revenue growth rate | 65.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 04 Nov 2024 |
Recent future growth updates
Recent updates
Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely?
Nov 17
Longeveron Inc.: A New Approach To Treat Alzheimer's
Oct 09Longeveron spikes after FDA’s Fast Track Designation for lead candidate
Aug 31Is Longeveron (NASDAQ:LGVN) In A Good Position To Invest In Growth?
Jul 15Longeveron rises ~20%, co to present Alzheimer's trial abstract at leading conference
Jul 07Longeveron: Small-Cap Biotech Targeting Large Alzheimer's Market
May 06Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 5 | -24 | N/A | N/A | 1 |
| 12/31/2025 | 2 | -22 | N/A | N/A | 3 |
| 12/31/2024 | 2 | -25 | N/A | N/A | 3 |
| 6/30/2024 | 1 | -28 | -17 | -16 | N/A |
| 3/31/2024 | 1 | -22 | -17 | -16 | N/A |
| 12/31/2023 | 1 | -22 | -20 | -19 | N/A |
| 9/30/2023 | 1 | -21 | -18 | -17 | N/A |
| 6/30/2023 | 1 | -20 | -18 | -17 | N/A |
| 3/31/2023 | 1 | -20 | -17 | -16 | N/A |
| 12/31/2022 | 1 | -19 | -15 | -14 | N/A |
| 9/30/2022 | 1 | -18 | -15 | -13 | N/A |
| 6/30/2022 | 1 | -18 | -12 | -11 | N/A |
| 3/31/2022 | 1 | -17 | -12 | -11 | N/A |
| 12/31/2021 | 1 | -17 | -11 | -10 | N/A |
| 9/30/2021 | 2 | -14 | -9 | -9 | N/A |
| 6/30/2021 | 4 | -10 | -7 | -7 | N/A |
| 3/31/2021 | 4 | -7 | -5 | -5 | N/A |
| 12/31/2020 | 6 | -4 | -3 | -2 | N/A |
| 9/30/2020 | 6 | -3 | -2 | -2 | N/A |
| 12/31/2019 | 6 | -3 | -3 | -2 | N/A |
| 12/31/2018 | 2 | -6 | -5 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LGVN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LGVN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LGVN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LGVN's revenue (65.2% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: LGVN's revenue (65.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LGVN's Return on Equity is forecast to be high in 3 years time